Please refer to the attached annexure.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Kothari Fermentation & Biochem Ltd, at its meeting held on February 13, 2026, approved the unaudited financial results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report by statutory auditors Kothari Kuldeep & Co. The company also approved an amendment to its Related Party Transactions Policy. For Q3 FY26, revenue from operations rose modestly to Rs. 3,194.97 lakhs from Rs. 3,053.03 lakhs in Q3 FY25, but the company slipped into a net loss of Rs. 37.84 lakhs versus a profit of Rs. 41.09 lakhs in the year-ago quarter. For the nine months ended December 31, 2025, revenue declined to Rs. 7,966.39 lakhs from Rs. 8,205.23 lakhs, while the net loss widened sharply to Rs. 458.03 lakhs from Rs. 24.13 lakhs. Total expenses rose faster than revenue, indicating continued margin pressure in the yeast business.
The widening losses and decline in nine-month revenue are negative signals for shareholders, reflecting cost pressures outpacing topline growth. However, the sequential improvement in Q3 (loss narrowed from Rs. 307.72 lakhs in Q2 to Rs. 37.84 lakhs) and double-digit revenue growth from the previous quarter may provide some near-term comfort to investors.